TY  - GEN 
AU  - Pérez Ramírez, Cristina
AU  - Cañadas Garre, Marisa
AU  - Molina, Miguel Ángel
AU  - Cabeza-Barrera, José
AU  - Faus Dader, María José
PY  - 2019
UR  - https://hdl.handle.net/10481/100129
AB  - EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the treatment of choice for advanced-stage (IIIB-IV) NSCLC patients with mutations in EGFR. However, EGFR-TKIs clinical outcomes vary from person to person and these inter-individual differences may be...
LA  - eng
PB  - Elsevier
KW  - EGFR tyrosine kinase inhibitors
KW  - Non-small cell lung cancer
KW  - Polymorphisms
KW  - Response
KW  - Survival
KW  - Toxicity
TI  - Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients
DO  - 10.1016/j.mrrev.2019.04.001.
ER  -